Lymphatic Filariasis: Treatment, Epidemiology & Control

Treatment & Management Options

Elephantiasis – Lymphatic Filariasis

DRUG TREATMENTS

Diethylcarbamazine (DEC)

Kills microfilariae & adult worms; given as single dose or over 12 days

Albendazole

400mg twice daily for 2 weeks; destroys adult worms

Ivermectin

200–400 mcg/kg; targets microfilariae

COMBINATION THERAPIES

DEC + Albendazole

Standard 2-drug combination

Triple therapy

Ivermectin + DEC + Albendazole (India's 2018 APELF program)

Ivermectin + Albendazole

Used where onchocerciasis co-exists

OTHER THERAPIES (Morbidity Management)

Lymphedema:

Limb hygiene, elevation, compression bandaging, exercise

Hydrocele:

Surgical correction

Acute adenolymphangitis:

Antibiotics + antifungals

Emerging:

Oxfendazole (macrofilaricide under clinical trials)

Elephantiasis – Lymphatic Filariasis

Vaccination & Control Programs

NO VACCINE EXISTS

Currently no approved vaccine for lymphatic filariasis

Experimental subunit vaccines are in clinical trials

9.7 BILLION+

treatments delivered globally since 2000

WHO GLOBAL PROGRAMME (GPELF)

<strong>Launched in 2000</strong> — goal: eliminate LF as a public health problem by 2030

<strong>2-Pillar Strategy:</strong><br>1. Interrupt transmission via MDA<br>2. Morbidity Management & Disability Prevention

MASS DRUG ADMINISTRATION (MDA)

Annual doses to entire at-risk populations for ≥5 years

<strong>Coverage target:</strong> ≥65% of at-risk population

<strong>74% decline</strong> in global infections since program start

<strong>58 of 72 endemic countries</strong> (80%) met criteria by 2023

VECTOR CONTROL

Insecticide-treated bed nets (ITNs)

Indoor residual spraying (IRS) of homes

Larval source management for Culex mosquitoes

MORBIDITY MANAGEMENT

Lymphedema management training for communities

Surgical correction programs for hydrocele

Psychosocial and emotional support

Epidemiology

Prevalence, Incidence & Burden of Lymphatic Filariasis

120.5M

Cases Globally (2021)

1.3B

People at Risk (73 Countries)

40M

Suffer Long-term Complications

>7.6K

Oceania Age-standardised Prevalence (per 100k)

Top Affected Countries

India

33.38 million cases (33%)

Indonesia

4.26 million cases

+ Nigeria (2.85M cases) → Together = 71% of global burden

Morbidity & Mortality

Rarely directly fatal, but causes significant life-long disability natively.

Leading cause of disability in tropical regions globally.

Disability-adjusted life years (DALYs) are declining since 1990 due to MDA programs.

Sydney / Australia Context

NOT endemic in Australia — last autochthonous case was reported in 1956.

Imported cases documented in migrants & returning travellers from PNG, Indonesia, Philippines, and India.

Susceptible Culex mosquitoes ARE present in Sydney — posing a theoretical re-introduction risk.

ADF personnel deployed to Timor-Leste/PNG: seroconversion risk assessed as very low.

Pathogen & Disease Images

Wuchereria bancrofti – Causative Agent of Lymphatic Filariasis

Wuchereria bancrofti microfilaria – light microscopy showing the slender, sheathed larval worm in peripheral blood

Clinical elephantiasis – gross lymphedema of lower limbs caused by lymphatic obstruction from adult filarial worms

PATHOGEN

Wuchereria bancrofti (90% of cases), Brugia malayi, Brugia timori

TRANSMISSION

Bite of infected Culex, Anopheles, or Aedes mosquitoes

LIFECYCLE

Microfilariae → L3 larvae (mosquito) → adult worms in lymphatics

ADULT WORM SIZE

Female 80–100mm, Male 40mm